KalVista Q1 2021 Earnings Report

KalVista reported financial results for the first fiscal quarter ended July 31, 2020.

Key Takeaways

KalVista Pharmaceuticals reported no revenue for the first fiscal quarter ended July 31, 2020, compared to $3.4 million for the same period in the prior fiscal year. Research and development expenses were $11.2 million, compared to $9.7 million for the same period in the prior fiscal year. Net loss was $10.8 million, or $(0.61) per share, compared to a net loss of $7.3 million, or $(0.42) per share, for the same period in the prior fiscal year.

KVD900 Phase 2 trial met enrollment target, with data expected in Q4 2020.

Completing formulation studies for KVD824, with pharmacokinetic and pharmacodynamic data expected later this year before starting a Phase 2 clinical trial.

Submitted a Pediatric Investigational Plan (PIP) to the European Medicines Agency (EMA) for KVD900.

Cash, cash equivalents and marketable securities were $64.3 million as of July 31, 2020, compared to $67.7 million as of April 30, 2020.

EPS

-$0.61

Previous year: -$0.42